Skip to main content
University of Wisconsin–Madison
UW Crest
Ophthalmology and Visual Sciences
  • Home
  • About Us Expand Collapse
    • About Us
    • Alumni
    • Careers
    • Directory
    • Giving
    • Leadership
  • Education Expand Collapse
    • Clinical Fellowships
    • Global Ophthalmology
    • Ophthalmology Clerkship
    • Orthoptist Training Program
    • Pre-Residency Fellowships
    • Residency Program
    • Vision Research Opportunities
    • Vision Research Training Program
    • Visiting Medical Students
  • Research Expand Collapse
    • A-EYE Research Unit
    • Clinical Eye Research Unit
    • Laboratories
    • Publications
    • Research Resources
    • Vision Research Core
    • Vision Research Training Program
    • WAIVS
    • Wisconsin Reading Center
  • Global Ophthalmology
  • People First
  • Events
  • Giving
  • News

CATALINA

Posted on December 1, 2020

A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA)

Sponsor: NGM Biopharmaceuticals, Inc.

CLINICALTRIALS.GOV

Posted in Age-related Macular Degeneration, Clinical Trials, Geographic Atrophy, Kathleen Schildroth, Past

Post navigation

Previous post: DOVS Mentee Presents at Medical Student Research Forum
Next post: CHM SURVEY TRIAL

Archives

Categories

Site footer content



University logo that links to main university website


Quick Links

  • News
  • Contact Us
  • Giving
  • Intranet Login
  • UW-Madison School of Medicine and Public Health

Contact Us

  • 2828 Marshall Court
    Madison, WI 53705
    • facebook
    • instagram
    • linkedin

Website feedback, questions or accessibility issues: webmaster@ophth.wisc.edu.

This site was built using the UW Theme | Privacy Notice | © 2025 Board of Regents of the University of Wisconsin System.